533 related articles for article (PubMed ID: 10412264)
1. [Experience with ambulatory radioiodine therapy of hyperthyroidism].
Róka R; Séra T; Valkusz Z; Julesz J; Csernay L; Pávics L
Orv Hetil; 1999 Jun; 140(23):1291-5. PubMed ID: 10412264
[TBL] [Abstract][Full Text] [Related]
2. [Characterization of therapy failures in radioiodine therapy of Graves' disease without simultaneous antithyroid agents].
Sabri O; Zimny M; Schreckenberger M; Reinartz P; Nowak B; Ostwald E; Schäfer W; Block S; Setani K; Büll U
Nuklearmedizin; 2001 Feb; 40(1):1-6. PubMed ID: 11373933
[TBL] [Abstract][Full Text] [Related]
3. [Treatment of hyperthyroidism caused by Graves' disease or toxic multinodular goitre by radioiodine: over 80% cure retrospectively after one calculated dose].
Bakker SC; Zanin DE; Zweers EJ
Ned Tijdschr Geneeskd; 2002 Sep; 146(39):1837-41. PubMed ID: 12382370
[TBL] [Abstract][Full Text] [Related]
4. Radioiodine therapy compared in patients with toxic nodular or Graves' hyperthyroidism.
Franklyn JA; Daykin J; Holder R; Sheppard MC
QJM; 1995 Mar; 88(3):175-80. PubMed ID: 7767667
[TBL] [Abstract][Full Text] [Related]
5. [Radioiodine therapy of autonomously functioning thyroid nodules and Graves' disease].
Guhlmann CA; Rendl J; Börner W
Nuklearmedizin; 1995 Feb; 34(1):20-3. PubMed ID: 7724360
[TBL] [Abstract][Full Text] [Related]
6. [Results of radioiodine therapy in different forms of hyperthyroidism in relation to the planned dosage].
Moser E
Aktuelle Radiol; 1992 Jul; 2(4):179-87. PubMed ID: 1504115
[TBL] [Abstract][Full Text] [Related]
7. Long-term follow-up study of radioiodine treatment of hyperthyroidism.
Metso S; Jaatinen P; Huhtala H; Luukkaala T; Oksala H; Salmi J
Clin Endocrinol (Oxf); 2004 Nov; 61(5):641-8. PubMed ID: 15521969
[TBL] [Abstract][Full Text] [Related]
8. [Radioiodine treatment of hyperthyroidism using a simplified dosimetric approach. Clinical results].
Giovanella L; De Palma D; Ceriani L; Vanoli P; Garancini S; Tordiglione M; Tarolo GL
Radiol Med; 2000 Dec; 100(6):480-3. PubMed ID: 11307510
[TBL] [Abstract][Full Text] [Related]
9. Graves' disease and radioiodine therapy. Is success of ablation dependent on the achieved dose above 200 Gy?
Kobe C; Eschner W; Sudbrock F; Weber I; Marx K; Dietlein M; Schicha H
Nuklearmedizin; 2008; 47(1):13-7. PubMed ID: 18278207
[TBL] [Abstract][Full Text] [Related]
10. Determination of the optimal minimum radioiodine dose in patients with Graves' disease: a clinical outcome study.
Howarth D; Epstein M; Lan L; Tan P; Booker J
Eur J Nucl Med; 2001 Oct; 28(10):1489-95. PubMed ID: 11685491
[TBL] [Abstract][Full Text] [Related]
11. Graves' ophthalmopathy and 131I therapy.
Marcocci C; Bartalena L; Tanda ML; Manetti L; Dell'Unto E; Mazzi B; Rocchi R; Barbesino G; Pinchera A
Q J Nucl Med; 1999 Dec; 43(4):307-12. PubMed ID: 10731781
[TBL] [Abstract][Full Text] [Related]
12. [Results of radioiodine therapy of manifest hyperthyroidism and autonomous struma with euthyroidism].
Berding G; Schicha H
Nuklearmedizin; 1990 Aug; 29(4):158-65. PubMed ID: 2216811
[TBL] [Abstract][Full Text] [Related]
13. A predictive mathematical model for the calculation of the final mass of Graves' disease thyroids treated with 131I.
Traino AC; Di Martino F; Grosso M; Monzani F; Dardano A; Caraccio N; Mariani G; Lazzeri M
Phys Med Biol; 2005 May; 50(9):2181-91. PubMed ID: 15843745
[TBL] [Abstract][Full Text] [Related]
14. Radioactive iodine therapy in Graves' hyperthyroidism.
Sankar R; Sripathy G
Natl Med J India; 2000; 13(5):246-51. PubMed ID: 11190053
[TBL] [Abstract][Full Text] [Related]
15. [Paradoxical effect of radioiodine therapy in functional thyroid autonomy and mild immunothyropathy].
Dunkelmann S; Rudolph F; Prillwitz A; Groth P; Schümichen C
Nuklearmedizin; 1998 Jan; 37(1):23-9. PubMed ID: 9467166
[TBL] [Abstract][Full Text] [Related]
16. Administration of additional inactive iodide during radioiodine therapy for Graves' disease: who might benefit?
Dietlein M; Moka D; Reinholz U; Schmidt M; Schomäcker K; Schicha H; Wellner U
Nuklearmedizin; 2007; 46(3):77-84. PubMed ID: 17549318
[TBL] [Abstract][Full Text] [Related]
17. Treatment of Graves' hyperthyroidism--prognostic factors for outcome.
Alfadda A; Malabu UH; El-Desouki MI; Al-Rubeaan KA; Al-Ruhaily AD; Fouda MA; Al-Maatouq MA; Sulimani RA
Saudi Med J; 2007 Feb; 28(2):225-30. PubMed ID: 17268701
[TBL] [Abstract][Full Text] [Related]
18. Relation between therapy for hyperthyroidism and the course of Graves' ophthalmopathy.
Bartalena L; Marcocci C; Bogazzi F; Manetti L; Tanda ML; Dell'Unto E; Bruno-Bossio G; Nardi M; Bartolomei MP; Lepri A; Rossi G; Martino E; Pinchera A
N Engl J Med; 1998 Jan; 338(2):73-8. PubMed ID: 9420337
[TBL] [Abstract][Full Text] [Related]
19. Radioiodine therapy in Graves' disease based on tissue-absorbed dose calculations: effect of pre-treatment thyroid volume on clinical outcome.
Reinhardt MJ; Brink I; Joe AY; Von Mallek D; Ezziddin S; Palmedo H; Krause TM
Eur J Nucl Med Mol Imaging; 2002 Sep; 29(9):1118-24. PubMed ID: 12192554
[TBL] [Abstract][Full Text] [Related]
20. [Graves' disease nd toxic nodular goiter--radioiodine therapy].
Schicha H; Dietlein M
Nuklearmedizin; 2002 Apr; 41(2):63-70. PubMed ID: 11989300
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
